Daily Stock Analysis, ABUS, Arbutus Biopharma Corp, priceseries

Arbutus Biopharma Corp. Daily Stock Analysis
Stock Information
Open
3.40
Close
3.30
High
3.45
Low
3.25
Previous Close
3.35
Daily Price Gain
-0.05
YTD High
3.49
YTD High Date
Apr 4, 2017
YTD Low
2.35
YTD Low Date
Jan 24, 2017
YTD Price Change
0.80
YTD Gain
32.00%
52 Week High
5.48
52 Week High Date
Apr 25, 2016
52 Week Low
2.35
52 Week Low Date
Jan 24, 2017
52 Week Price Change
-1.99
52 Week Gain
-37.62%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 7. 2015
14.87
Feb 2. 2015
24.90
17 Trading Days
67.42%
Link
Company Information
Stock Symbol
ABUS
Exchange
NasdaqGS
Company URL
www.arbutusbio.com
Company Phone
-
CEO
Mark J. Murray
Headquarters
-
Business Address
-
Sector
Healthcare
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

Arbutus Biopharma Corp. is a biopharmaceutical company. It focuses on on discovering, developing and commercializing a cure for patients suffering from chronic HBV infection, a disease of the liver caused by the hepatitis B virus. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.

Description

Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically infected with HBV. Its HBV product candidates also comprise ARB-1740, a RNAi HBV candidate that is in preclinical studies; small molecule cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; HBV core protein assembly inhibitors; ARB-1598, a toll-like receptor; surface antigen secretion inhibitors; cccDNA epigenetic modifiers; stimulator of interferon genes agonists; and cyclophilin inhibitor drug candidates, including OCB-030 and other cyclophilin inhibitors. In addition, it develops TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02,whichis in Phase III clinical study, a therapeutic targeting transthyretin mediated amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for treating Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.